MalarImDB: An open-access literature-based malaria immunology database

Trends in Parasitology

Volumn 30, Issue 6, 2014, Pages 309-316

  Deroost, Katrien ^a   Opdenakker, Ghislain ^a   Van den Steen, Philippe E ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Blood stage malaria; Cerebral malaria; Clinical studies; MalarImDB; Mouse models; Plasmodium

Indexed keywords

ANGIOPOIETIN 2; GAMMA INTERFERON INDUCIBLE PROTEIN 10;

DATA BASE; HUMAN; IMMUNOLOGY; INFORMATION PROCESSING; MALARIA; MALARIMDB; MEDICAL LITERATURE; MEDICAL RESEARCH; NONHUMAN; PLASMODIUM MALARIAE; REVIEW; SEARCH ENGINE;

BLOOD-STAGE MALARIA; CEREBRAL MALARIA; CLINICAL STUDIES; MALARIMDB; MOUSE MODELS; PLASMODIUM;

ACCESS TO INFORMATION; ALLERGY AND IMMUNOLOGY; ANIMALS; DATABASES, FACTUAL; HUMANS; LITERATURE; MALARIA; TRANSCRIPTOME;

EID: 84901195619     PISSN: 14714922     EISSN: 14715007     Source Type: Journal    
DOI: 10.1016/j.pt.2014.04.006     Document Type: Review

References (47)

1. Langhorne J., et al. Immunity to malaria: more questions than answers. Nat. Immunol. 2008, 9:725-732.
2. Riley E.M., Stewart V.A. Immune mechanisms in malaria: new insights in vaccine development. Nat. Med. 2013, 19:168-178.
3. Alonso P.L., Tanner M. Public health challenges and prospects for malaria control and elimination. Nat. Med. 2013, 19:150-155.
4. Miller L.H., et al. Malaria biology and disease pathogenesis: insights for new treatments. Nat. Med. 2013, 19:156-167.
5. Day N., Dondorp A.M. The management of patients with severe malaria. Am. J. Trop. Med. Hyg. 2007, 77:29-35.
6. Higgins S.J., et al. Immunopathogenesis of falciparum malaria: implications for adjunctive therapy in the management of severe and cerebral malaria. Expert Rev. Anti Infect. Ther. 2011, 9:803-819.
7. Agnandji S.T., et al. First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children. N. Engl. J. Med. 2011, 365:1863-1875.
8. Agnandji S.T., et al. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N. Engl. J. Med. 2012, 367:2284-2295.
9. Wells T.N., et al. New medicines to improve control and contribute to the eradication of malaria. Nat. Rev. Drug Discov. 2009, 8:879-891.
10. Baird J.K. Evidence and implications of mortality associated with acute Plasmodium vivax malaria. Clin. Microbiol. Rev. 2013, 26:36-57.
11. Seydel K.B., et al. The distribution and intensity of parasite sequestration in comatose Malawian children. J. Infect. Dis. 2006, 194:208-215.
12. Deroost K., et al. Improved methods for haemozoin quantification in tissues yield organ- and parasite-specific information in malaria-infected mice. Malar. J. 2012, 11:166.
13. Cunnington A.J., et al. Stuck in a rut? Reconsidering the role of parasite sequestration in severe malaria syndromes. Trends Parasitol. 2013, 29:585-592.
14. Francischetti I.M., et al. Blood coagulation, inflammation, and malaria. Microcirculation 2008, 15:81-107.
15. Craig A., et al. The role of animal models for research on severe malaria. PLoS Pathog. 2012, 8:e1002401.
16. Wilson N.O., et al. CXCL4 and CXCL10 predict risk of fatal cerebral malaria. Dis. Markers 2011, 30:39-49.
17. Armah H.B., et al. Cerebrospinal fluid and serum biomarkers of cerebral malaria mortality in Ghanaian children. Malar. J. 2007, 6:147.
18. Jain V., et al. Plasma IP-10, apoptotic and angiogenic factors associated with fatal cerebral malaria in India. Malar. J. 2008, 7:83.
19. Molyneux M.E., et al. Circulating plasma receptors for tumour necrosis factor in Malawian children with severe falciparum malaria. Cytokine 1993, 5:604-609.
20. Deloron P., et al. Plasma levels of TNF-α soluble receptors correlate with outcome in human falciparum malaria. Eur. Cytokine Netw. 1994, 5:331-336.
21. Bygbjerg I.C., et al. Decreased plasma levels of factor II+VII+X correlate with increased levels of soluble cytokine receptors in patients with malaria and meningococcal infections. APMIS 1997, 105:150-156.
22. Dekker E., et al. Glucose production and gluconeogenesis in adults with uncomplicated falciparum malaria. Am. J. Physiol. 1997, 272:E1059-E1064.
23. Chang K.H., et al. Modulation of the course and outcome of blood-stage malaria by erythropoietin-induced reticulocytosis. J. Infect. Dis. 2004, 189:735-743.
24. Van den Steen P.E., et al. Immunopathology and dexamethasone therapy in a new model for malaria-associated acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 2010, 181:957-968.
25. Lovegrove F.E., et al. Parasite burden and CD36-mediated sequestration are determinants of acute lung injury in an experimental malaria model. PLoS Pathog. 2008, 4:e1000068.
26. Geurts N., et al. Insufficiently defined genetic background confounds phenotypes in transgenic studies as exemplified by malaria infection in Tlr9 knockout mice. PLoS ONE 2011, 6:e27131.
27. Perlmann P., et al. Contrasting functions of IgG and IgE antimalarial antibodies in uncomplicated and severe Plasmodium falciparum malaria. Am. J. Trop. Med. Hyg. 2000, 62:373-377.
28. Wilson N.O., et al. Pharmacologic inhibition of CXCL10 in combination with anti-malarial therapy eliminates mortality associated with murine model of cerebral malaria. PLoS ONE 2013, 8:e60898.
29. Morrell C.N., et al. Beta interferon suppresses the development of experimental cerebral malaria. Infect. Immun. 2011, 79:1750-1758.
30. Van den Steen P.E., et al. CXCR3 determines strain susceptibility to murine cerebral malaria by mediating T lymphocyte migration toward IFN-γ-induced chemokines. Eur. J. Immunol. 2008, 38:1082-1095.
31. Miu J., et al. Chemokine gene expression during fatal murine cerebral malaria and protection due to CXCR3 deficiency. J. Immunol. 2008, 180:1217-1230.
32. Campanella G.S., et al. Chemokine receptor CXCR3 and its ligands CXCL9 and CXCL10 are required for the development of murine cerebral malaria. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:4814-4819.
33. Hanum P.S., et al. Cytokine and chemokine responses in a cerebral malaria-susceptible or -resistant strain of mice to Plasmodium berghei ANKA infection: early chemokine expression in the brain. Int. Immunol. 2003, 15:633-640.
34. Nie C.Q., et al. IP-10-mediated T cell homing promotes cerebral inflammation over splenic immunity to malaria infection. PLoS Pathog. 2009, 5:e1000369.
35. Wilson N., et al. CXCL10 gene promoter polymorphism -1447A>G correlates with plasma CXCL10 levels and is associated with male susceptibility to cerebral malaria. PLoS ONE 2013, 8:e81329.
36. Taylor T.E., et al. Differentiating the pathologies of cerebral malaria by postmortem parasite counts. Nat. Med. 2004, 10:143-145.
37. De Souza J.B., et al. Early gamma interferon responses in lethal and nonlethal murine blood-stage malaria. Infect. Immun. 1997, 65:1593-1598.
38. D'Ombrain M.C., et al. Association of early interferon-γ production with immunity to clinical malaria: a longitudinal study among Papua New Guinean children. Clin. Infect. Dis. 2008, 47:1380-1387.
39. Omer F.M., et al. Differential induction of TGF-β regulates proinflammatory cytokine production and determines the outcome of lethal and nonlethal Plasmodium yoelii infections. J. Immunol. 2003, 171:5430-5436.
40. Li C., et al. Pathology of Plasmodium chabaudi chabaudi infection and mortality in interleukin-10-deficient mice are ameliorated by anti-tumor necrosis factor α and exacerbated by anti-transforming growth factor β antibodies. Infect. Immun. 2003, 71:4850-4856.
41. Kossodo S., et al. Interleukin-10 modulates susceptibility in experimental cerebral malaria. Immunology 1997, 91:536-540.
42. Conroy A.L., et al. Whole blood angiopoietin-1 and -2 levels discriminate cerebral and severe (non-cerebral) malaria from uncomplicated malaria. Malar. J. 2009, 8:295.
43. Lovegrove F.E., et al. Serum angiopoietin-1 and -2 levels discriminate cerebral malaria from uncomplicated malaria and predict clinical outcome in African children. PLoS ONE 2009, 4:e4912.
44. Moyes C.L., et al. Providing open access data online to advance malaria research and control. Malar. J. 2013, 12:161.
45. Gerlai R. Gene-targeting studies of mammalian behavior: is it the mutation or the background genotype?. Trends Neurosci. 1996, 19:177-181.
46. Wolfer D.P., et al. Knockout mice: simple solutions to the problems of genetic background and flanking genes. Trends Neurosci. 2002, 25:336-340.
47. Berer K., et al. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 2011, 479:538-541.